

September 13, 2019

Ms. Hope Johnson, PM 21 Document Processing Desk (NOTIF) Office of Pesticide Programs (7540P) U.S. Environmental Protection Agency Room S-4900, One Potomac Yard 2777 South Crystal Drive Arlington, VA 22202-4501

RE: A230.04 [ABN: Alterity 62.5 WG] (EPA Reg. No 91234-89)

Notification to Add New Registered Source of Active Ingredient per PRN 98-10

Dear Ms. Johnson:

Please find the enclosed Notification to update the Confidential Statement of Formula (CSF) for A230.04 (EPA Reg. No. 91234-89). Atticus, LLC is proposing the addition of an Alternate 2 Formulation to add new registered sources of active ingredients. The new sources are equivalent to the previous sources and are registered for at least the same uses for which A230.04 is registered. The new sources of active ingredients for Alternate 2 Formulation only slightly different in purity as the active ingredient source for the Basic CSF. Only minor adjustment is made accordingly to the solvent amount.

In support of this notification please find the enclosed documents:

- 1. Completed Application for Registration (EPA Form 8570-1)
- 2. One (1) copy of Alternate 2 Formulation CSF (EPA Form 8570-4) (dated 9/13/2019)
- 3. One (1) copy of Formulator's Exemption Statement (EPA Form 8570-27) (dated 9/13/2019)

The enclosed Alternate 2 Formulation is **IN ADDITION** the currently approved Basic CSF and Alternate 1 Formulation dated 8/26/2019 and 2/28/2019, respectively. Please feel free to contact me (984-465-4766; Dave.Bolin@AtticusLLC.com) if you have any questions or need any additional information.

This notification is consistent with the provisions of PR Notice 98-10 and EPA regulations at 40 CFR 152.46, and no other changes have been made to the labeling or the confidential statement of formula of this product. I understand that it is a violation of 18 U.S.C. Sec. 1001 to willfully make any false statement to EPA. I further understand that if this notification is not consistent with the terms of PR Notice 98-10 and 40 CFR 152.46, this product may be in violation of FIFRA and I may be subject to enforcement action and penalties under sections 12 and 14 of FIFRA.

Respectfully submitted,

Dave G. Bolin, Ph.D

Vice President - Regulatory Affairs